Clinical Trial Detail

NCT ID NCT02747004
Title A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib + Loperamide

Abemaciclib

Abemaciclib + Tamoxifen

Age Groups: adult

Additional content available in CKB BOOST